Abstract
The therapeutic strategy in breast cancer, as well as in other types of cancer, changes quite frequently. These changes result from the publication of the results of clinical trials or meta-analyses of several trials. An important contribution in identifying the best therapeutic strategies is also made by the reviews of the publications that target the same subject. In this context, the present article describes the new therapeutic approaches in advanced (metastatic) breast cancer, after the introduction in clinical practice of CDK inhibitors and PARP inhibitors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
